AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical to acquire worldwide development and commercialisation rights for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for non-small cell lung cancer (NSCLC).

• Licensing Agreement: AstraZeneca will make an upfront payment of US$600 million, with additional milestone payments of up to US$900 million, while Dizal Pharmaceutical will receive tiered royalties on global sales.
• Transaction Timeline: The agreement is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
• Approved Indication: Zegfrovy is approved in the United States and China for adults with locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

This summary is based on a news article published by BioSpectrum Asia.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.